Scott Rocklage Ph.D. has over 20 years of experience in the world of healthcare and its management and has been awarded several times for his stellar contributions to the medical world in general. He was able to join the 5 AM Ventures way back in 2003 as a partner and had become the manager in 2004.

He has been in leadership positions, and these have prepared him because currently he sits in several bards and oversees a lot of things around the country. He was the one which led to the successful approval of three new drugs:

Cubicin

  1. Telascan
  2. Omniscan

Success

Apart from that, he has entered six drugs into the clinical trials. As a leader who can inspire and lead to the betterment of the places that he serves, he has performed incredibly well. As an academic with the gift to invent, he has capitalized on that and has now registered over 30 patents that he invented or co-invented.

He conducted his research in the lab of Richard R. Schrock who won a Nobel Peace Prize in 2005. His publications which have been peer-reviewed having shown just how much of an academic he is which is something that has been proud of.

His Services

Over the years he has been in several positions that have included boards and other interests that have shaped who he is.

  • He has been the president of the Nycomed Salutar where he was also a Chief Executive Officer.

He held the R&D positions at Salutar and Catalytica.

He was serving as the board chair of Relypsa (NASDAQ: RLYP)

He was also on the board of Novira which was eventually acquired by J&J.

As of now, Scott Rocklage is serving as the Chairman on the board of the Rennovia, Cidara, and Kinestral.

  • He has been on the board of Epirasx and Pulmatrix.

Suffice to say that he has made a mark.

Alma Mater

He got his:

  • Bachelor of Science from The University of California in Chemistry.
  • He got his Ph.D. from MIT.

As an academic and an investor, he is just great.